2022 Revenues ($USD) : $386,905,000
2022 R&D spend : $47,665,000
2022 Number of Employees : 945
Fiscal Year End : 12/31/2021
Company CEO : Keith Grossman, president and CEO

Silicon Valley–based Nevro started in 2006 with the goal of helping patients suffering from chronic pain. The company's Senza SCS system provides 10 kHZ therapy to tens of thousands of patients across the globe. In early 2022, Nevro announced promising 12-month data from the Senza-NSRBP randomized controlled study of its 10 kHz spinal cord stimulation technology. Since early 2021, however, the company's stock price has steadily declined. After flirting with hitting $180 per share in January 2021, NVRO shares were trading below $50 in late August 2022. In the positive column, Nevro reached an $85 million settlement with Boston Scientific to settle intellectual property concerns.  –BB